According to Akebia Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.73438. At the end of 2022 the company had a P/E ratio of -1.13.
Year | P/E ratio | Change |
---|---|---|
2022 | -1.13 | -14.9% |
2021 | -1.33 | 31.52% |
2020 | -1.01 | -62.25% |
2019 | -2.68 | 11.19% |
2018 | -2.41 | -71.66% |
2017 | -8.50 | 193.85% |
2016 | -2.89 | -48.97% |
2015 | -5.67 | 2047.39% |
2014 | -0.2639 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
18.6 | -779.24% | ๐บ๐ธ USA | |
26.6 | -1,072.37% | ๐จ๐ญ Switzerland | |
10.1 | -470.87% | ๐บ๐ธ USA | |
-0.6656 | -75.66% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.